The importance of intensive medicine in the management of patients treated with CAR T-cells should not be underestimated. Speaking from the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany, Michael von Bergwelt, MD, PhD, of LMU Hospital Munich, Munich, Germany, discusses the importance of intensive care in this field, highlighting the capacity, resources and training issues that need to be addressed.